- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07222553
Studie naar de evaluatie van de farmacokinetiek, farmacodynamiek, veiligheid en verdraagbaarheid van Inebilizumab bij pediatrische deelnemers met IgG4-RD
Open-label, ongecontroleerd, multicenter onderzoek om de farmacokinetiek, farmacodynamiek, veiligheid en verdraagbaarheid van inebilizumab te evalueren bij kinderen van 2 jaar tot minder dan 18 jaar met immunoglobuline G4-gerelateerde ziekte (IgG4-RD)
The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD), as well as to assess the safety and tolerability, of inebilizumab in pediatric participants with IgG4-RD.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Amgen Call Center
- Telefoonnummer: 866-572-6436
- E-mail: medinfo@amgen.com
Studie Locaties
-
-
Ceará
-
Fortaleza, Ceará, Brazilië, 60140-025
- Werving
- Centro Oncologia Leonardo Da Vinci
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brazilië, 40110-060
- Werving
- Universidade Federal da Bahia - Hospital Universitario Professor Edgard Santos
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brazilië, 90035-903
- Werving
- Hospital de Clinicas de Porto Alegre
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100730
- Werving
- Peking Union Medical College Hospital
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 401122
- Werving
- Childrens Hospital of Chongqing Medical University
-
-
Hunan
-
Changsha, Hunan, China, 410000
- Werving
- The Second Xiangya Hospital of Central South University
-
-
-
-
-
Athens, Griekenland, 11527
- Werving
- General Children Hospital Panagioti and Aglaias Kyriakou
-
Athens, Griekenland, 11521
- Werving
- Euroclinic Children Hospital
-
-
-
-
-
Roma, Italië, 00165
- Werving
- IRCCS Ospedale Pediatrico Bambino Gesu
-
-
-
-
-
Warsaw, Polen, 02-637
- Werving
- Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im prof dr hab med Eleonory Reicher
-
Warsaw, Polen, 04-730
- Werving
- Instytut Pomnik-Centrum Zdrowia Dziecka
-
Wroclaw, Polen, 52-114
- Werving
- Szpital Specjalistyczny Im A Falkiewicza we Wroclawiu
-
-
-
-
Valencia
-
Valencia, Valencia, Spanje, 46026
- Werving
- Hospital Universitari i Politecnic La Fe
-
-
-
-
-
Ankara, Turkije (Türkiye), 06100
- Werving
- Hacettepe Universitesi Tip Fakultesi Hastanesi
-
Istanbul, Turkije (Türkiye), 34098
- Werving
- Istanbul Universitesi Cerrahpasa Tip Fakultesi
-
Istanbul, Turkije (Türkiye), 34764
- Werving
- Umraniye Egitim ve Arastirma Hastanesi
-
-
-
-
Florida
-
Tampa, Florida, Verenigde Staten, 33612
- Werving
- University of South Florida - Carol and Frank Morsani Center for Advanced Health Care
-
-
North Carolina
-
Chapel Hill, North Carolina, Verenigde Staten, 27599
- Werving
- University of North Carolina at Chapel Hill
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15224
- Werving
- University of Pittsburgh Medical Center Childrens Hospital of Pittsburgh
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Key Inclusion Criteria:
- Participants must weigh ≥ 17 kg to be eligible for enrollment.
- Participant has provided informed consent/assent before initiation of any study-specific activities/procedures. Participant's legally authorized representative has provided informed consent when the participant is legally too young to provide informed consent, and the participant has provided written assent based on local regulations and/or guidelines before any study-specific activities/procedures being initiated.
- Age 2 to < 18 years at the time of screening. For participants who reach the age of legal consent during the clinical study, notification will be required, and a new consent form must be signed by the participant for continuation in the study.
- Clinical diagnosis of IgG4-RD.
- Fulfillment of the 2019 American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) classification criteria as determined by the principal investigator (PI) at screening. Specifically, participants must meet the classification criteria entry requirements (including involvement of one of the following organs: pancreas, bile ducts/biliary tree, orbits, lungs, kidneys, lacrimal glands, major salivary glands, retroperitoneum, aorta, pachymeninges, or thyroid gland [Riedel's thyroiditis]), must not meet any of the classification criteria exclusions, and must achieve at least 20 classification criteria inclusion points.
- Receipt of all age-appropriate and locally-required vaccinations before screening.
- Participants requiring treatment in addition to or other than glucocorticoids (GCs) for IgG4-RD according to PI's assessment at screening.
- Participants who are on GCs for the treatment of IgG4-RD should remain on a stable dose for at least 2 weeks before enrollment (Day 1). Tapering post enrollment will be at PI's discretion.
Key Exclusion Criteria:
-
Participants with any of the following abnormal liver function tests in the presence of hepatobiliary IgG4-RD activity:
- aspartate aminotransferase (AST) > 10 × upper limit of normal (ULN)
- alanine aminotransferase (ALT) > 10 × ULN
- total bilirubin (TBL) > 5 × ULN Screening liver function tests may be repeated before Day 1 to permit abnormal values due to hepatobiliary IgG4-RD activity to respond to GC treatment.
-
Evidence of significant hepatic, renal, or metabolic dysfunction or significant hematological abnormality, including any of the following at screening (one repeat test may be conducted to confirm results within the same screening period):
- platelet count < 75000/μL (or < 75 × 109/L)
- absolute neutrophil count < 1200 cells/μL
- total Ig < 600 mg/dL
- CD4 T lymphocyte count < 300 cells/µL
- hemoglobin < 8 g/dL (or < 80 g/L).
-
Estimated glomerular filtration rate < 45 mL/min/1.73 m^2.
-
B-cell counts < one-half of the lower limit of normal (LLN) for age according to the central laboratory.
-
Diagnosed with a concurrent autoimmune disease that is uncontrolled or requires any prohibited medication (unless approved by the medical monitor).
-
Clinically significant serious active or chronic viral, bacterial, or fungal infection that requires treatment with anti-infectives, hospitalization, or, in the investigator's opinion, represents an additional risk to the participant, within 2 months before Day 1 of study.
-
Known history of congenital or acquired immunodeficiency (eg, due to human immunodeficiency virus [HIV] infection, splenectomy, immunosuppression-related or idiopathic T-cell deficiencies) that predisposes the participant to infection.
-
Positive test for chronic hepatitis B infection at screening, defined as either: (1) Positive hepatitis B surface antigen (HBsAg); or (2) Positive hepatitis B core antibody (anti-HBc) PLUS negative hepatitis B surface antibody (anti-HBs). Note: Participants with a positive anti-HBs only, or a positive anti-HBc plus positive anti-HBs and negative HBsAg, are eligible to enroll.
-
Receipt of any of the following before Day 1: alemtuzumab, total lymphoid irradiation, bone marrow transplant, T-cell vaccination therapy.
-
Receipt of any of the following within 2 months before Day 1: azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, cyclophosphamide, tocilizumab, satralizumab, eculizumab, and mitoxantrone.
-
Receipt of rituximab or any experimental B-cell depleting agent (eg, ocrelizumab, obinutuzumab, ofatumumab, inebilizumab), or any non-depleting B-cell-directed therapy (eg, belimumab), abatacept, within 6 months before screening unless B-cell counts have returned to ≥ one-half the LLN.
-
Receipt of any live or attenuated vaccine (administration of inactivated [killed] vaccine is acceptable) within 4 weeks before Day 1, Bacillus Calmette-Guérin vaccine within 1 year of screening, or blood transfusion within 4 weeks before screening or during screening.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Inebilizumab
Participants will receive Inebilizumab via intravenous (IV) infusion. |
Inebilizumab will be administered via IV infusion. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Maximale plasmaconcentratie (Cmax) van Inebilizumab
Tijdsspanne: Tot dag 561
|
Tot dag 561
|
|
Oppervlak onder de plasmakoncentratie-tijdcurve (AUC) van Inebilizumab
Tijdsspanne: Tot Dag 561
|
Tot Dag 561
|
|
Klaring (CL) van Inebilizumab
Tijdsspanne: Tot en met dag 561
|
Tot en met dag 561
|
|
Terminale halfwaardetijd (t½) van Inebilizumab
Tijdsspanne: Tot dag 561
|
Tot dag 561
|
|
Volume van distributie in steady-state (Vss) van Inebilizumab
Tijdsspanne: Tot Dag 561
|
Tot Dag 561
|
|
Verandering ten opzichte van de uitgangswaarde in CD20+ B-celaantallen
Tijdsspanne: Basislijn en dag 561
|
Basislijn en dag 561
|
|
Aantal deelnemers met bijwerkingen (AEs)
Tijdsspanne: Tot dag 561
|
Tot dag 561
|
|
Aantal deelnemers met ernstige bijwerkingen (SAE's)
Tijdsspanne: Baseline tot en met dag 561
|
Baseline tot en met dag 561
|
|
Aantal deelnemers met gebeurtenissen van belang (EOI's)
Tijdsspanne: Baseline tot en met dag 561
|
Baseline tot en met dag 561
|
|
Aantal deelnemers met klinisch significante veranderingen ten opzichte van de uitgangswaarden in laboratoriumparameters
Tijdsspanne: Baseline tot en met dag 561
|
Baseline tot en met dag 561
|
|
Aantal deelnemers met klinisch significante veranderingen in vitale functies ten opzichte van de uitgangswaarde
Tijdsspanne: Baseline tot en met dag 561
|
Baseline tot en met dag 561
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Tijd tot eerste behandelde opvlamming gedurende 52 weken
Tijdsspanne: Tot week 52
|
Tot week 52
|
|
Percentage van deelnemers zonder opvlammingen gedurende 52 weken
Tijdsspanne: Tot week 52
|
Tot week 52
|
|
Jaarlijks gecorrigeerd opflakkeringpercentage over 52 weken
Tijdsspanne: Tot Week 52
|
Tot Week 52
|
|
Aanwezigheid van Antigeneesmiddel Antistoffen (ADA) Voor en Na Start van Behandeling
Tijdsspanne: Dag 1 tot Dag 561
|
Dag 1 tot Dag 561
|
|
Percentage verlaging ten opzichte van baseline in dagelijkse glucocorticoid dosis na week 52
Tijdsspanne: Basislijn en week 52
|
Basislijn en week 52
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: MD, Amgen
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 20240202
- 2025-520988-41-00 (Ctis)
- 2025 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
IPD-tijdsbestek voor delen
Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD-toegangscriteria voor delen
Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ICF
- MVO
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .